DBV Technologies S.A. (DBVT) SEC Filings & Earnings Calls

Regulatory outcome uncertain; FDA may request additional data or deny approval.

“BLA submission does not guarantee FDA approval; regulatory review process involves significant uncertainty.”

Regulatory risk: BLA submission timing and FDA approval uncertainty; high cash burn rate; no approved product revenue.

“BLA submission anticipated Q3 2026; net loss widening; cash $174.9M funding into Q3 2027.”

No Revenue

“The Company did not generate Revenue from operating activities.” · word for word

BLA Submission Delay

“the Company announced that it will take the required time to incorporate the FDA’s feedback and anticipates the BLA filing to occur in the third quarter of 2026.”

High Cash Burn

“Net cash used for operating activities was $101.7 million for the six months ended June 30, 2026.” · word for word

Foreign Exchange Risk

“During the six months ended June 30, 2026, the euro depreciated against the U.S. dollar, resulting in a $(5.3) million unfavorable foreign currency translation adjustment.” · word for word

Dependence on Financing

“The Company may seek additional capital in the future through new or existing financing strategies to support its long-term corporate strategy.” · word for word

Regulatory approval risk for VIASKIN Peanut Patch; FDA review process uncertainty

“BLA submission update; working collaboratively with FDA to optimize review process”

Clinical and regulatory risk: Viaskin Peanut approval not yet obtained

“CEO severance package requires 'Viaskin Peanut is approved in a major market' as a condition, indicating approval is not yet achieved.”

Operating losses and reliance on external financing

“Given our historical operating losses and reliance on external financings, we may seek additional capital as we prepare for the launch of Viaskin Peanut, if approved.” · word for word

Dilution risk from equity authorizations

“the maximum global nominal amount of the share capital increases which may be completed ... cannot exceed EUR29,604,244, i.e. approximately 100% of our share capital as of March 26, 2026” · word for word

Widening net loss and increased cash burn rate as the company invests in BLA submission and commercial infrastructure.

“Net loss increased to $47.6M from $27.1M; operating cash outflow increased to $49M from $20M.”

Regulatory and commercial execution risk: BLA submission and potential launch dependent on FDA approval.

“BLA filing in the first half of this year and commercial preparedness for the U.S. launch... if approved.” · word for word

Cash runway limited to Q2 2027; potential need for additional financing

“Based on its current operations, plans, and assumptions, Management estimates that the Company is sufficiently funded to run its operations into the second quarter of 2027” · word for word

No approved products; regulatory and commercial execution risk

“The Company does not generate revenue and continues to prepare for the potential launch of its first product in the United States and in the European Union, if approved.” · word for word

Foreign exchange risk from USD depreciation

“This exposure has been increased by the continued depreciation of the U.S. dollar observed over the past year, which increases volatility and uncertainty regarding foreign-currency-denominated operating costs.” · word for word

CEO compensation heavily weighted toward equity and performance-based incentives, but severance is tied to specific milestones

“Severance package will therefore be paid to the Chief Executive Officer if all the following criteria are met: • Viaskin Peanut approved on a major market; • Construction of an EPIT pipeline with three trials in progress; • 6 months’ cash flow...” · word for word

Net loss widened to $147M; operating cash burn remains high at $121M.

“Net loss was $147.0 million... Net cash used for operating activities was $121.2 million.” · word for word

Dependence on successful BLA submission and FDA approval for revenue generation.

“BLA Submission for 4-7 year olds anticipated in the first half of 2026... if approved.” · word for word

Regulatory approval risk

“We cannot be certain that we will be able to obtain regulatory approval for, or successfully commercialize, Viaskin products.” · word for word

Clinical trial failure risk

“Our product candidates have undergone and/or will be required to undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for which there is a high risk of failure.” · word for word

Funding risk

“We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.” · word for word

Competition from GSK ozureprubart

“Following its acquisition of RAPT Therapeutics in March 2026, GlaxoSmithKline (“GSK”) is developing ozureprubart, an IgE‑pathway inhibitor with potential relevance for food‑allergy treatment.” · word for word

Manufacturing and supply chain risk

“Access to raw materials and products necessary for the conduct of clinical trials, for commercialization, if approved, and manufacturing of our product candidates and product, if any, is not guaranteed.” · word for word

Going concern uncertainty: cash not sufficient for 12 months; substantial doubt raised.

“These conditions and events raise substantial doubt about the Company’s ability to continue as a going concern.” · word for word

Reliance on external financing: PIPE and ATM provide near-term liquidity but future access uncertain.

“Access to additional capital in the future remains subject to market conditions and investor interest.” · word for word

Clinical trial risk: VITESSE Phase 3 primary endpoint topline expected Q4 2025; failure could impair warrant exercise and funding.

“The VITESSE Phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of the warrants.” · word for word

Going concern uncertainty

“the Company estimates that its cash and cash equivalents are sufficient to fund its operations into the third quarter of 2026. As such, cash and cash equivalents are not sufficient to fund operations for the next 12 months, and these conditions and events raise substantial doubt about the Company's ability to continue as a going concern” · word for word

Clinical trial failure risk

“The VITESSE Phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of the warrants (results expected by the fourth quarter of 2025).” · word for word

Dilution risk

“The financing resulted in an immediate dilution of 22.4% and a maximal dilution of up to 73.7% of existing shareholders (on a non-diluted basis) if all the warrants in the Offering are exercised in full.” · word for word